Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
19 juil. 2024 16h05 HE
|
Longeveron
Longeveron announces closing of previously announced registered direct offering, raising $9 million in gross proceeds.
Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
18 juil. 2024 08h45 HE
|
Longeveron
Longeveron announces $9.0 million registered direct offering.
Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease
17 juil. 2024 08h00 HE
|
Longeveron
Longeveron announces FDA has granted Fast Track designation to cellular therapy Lomecel-B(TM) for the treatment of mild Alzheimer’s Disease.
Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease
10 juil. 2024 07h30 HE
|
Longeveron
Longeveron® Announces U.S. FDA Grants Lomecel-B(TM) Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease
Neha Motwani Elected to Longeveron® Board of Directors
09 juil. 2024 09h00 HE
|
Longeveron
Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors
Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors
08 juil. 2024 09h00 HE
|
Longeveron
Gene therapy pioneer Dr. Roger Hajjar elected to Longeveron Board of Directors as company advances it novel cellular therapy across multiple indications.
Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction
18 juin 2024 16h48 HE
|
Longeveron
Longeveron raises $4.4 Million in gross proceeds from warrant exercise transaction to fund development of its cellular therapy Lomecel-B
Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
17 juin 2024 09h00 HE
|
Longeveron
Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.
Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds
17 juin 2024 08h38 HE
|
Longeveron
Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds
Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease
11 juin 2024 09h00 HE
|
Longeveron
Investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B as a potential adjunct treatment for HLHS.